AGC1 Antibody

What is AGC1 and why do researchers study it?

AGC1 has two distinct meanings in research contexts. First, it refers to Aggrecan core protein, a major proteoglycan in cartilage that functions to resist compression, providing protection for joint movement and against injury . Second, it can refer to Aspartate-glutamate carrier 1, a mitochondrial transporter essential for aspartate export from mitochondria to cytosol, supporting cell proliferation and redox homeostasis .

The selection of appropriate antibodies depends on which AGC1 protein you're investigating. For cartilage research, anti-Aggrecan antibodies are widely used to study joint disorders and cartilage development. For mitochondrial research, antibodies against the aspartate-glutamate carrier help investigate cellular metabolism, especially in cancer and neurological research .

How do I choose the appropriate AGC1 antibody for my experiment?

Choose your AGC1 antibody based on:

• Target specificity: Confirm which AGC1 protein you're studying (Aggrecan or Aspartate-glutamate carrier)

• Application compatibility: Verify the antibody is validated for your specific application (Western blot, ELISA, IHC, etc.)

• Host species: Consider compatibility with other antibodies in multiplex experiments

• Clonality: Monoclonal antibodies (like 4D7.1) offer high specificity for defined epitopes , while polyclonal antibodies may provide broader detection

• Reactivity: Ensure the antibody recognizes your species of interest

For critical experiments, preservative-free recombinant antibodies may offer improved reproducibility and reduced batch-to-batch variation .

What are the fundamental differences between antibodies for Aggrecan versus Aspartate-glutamate carrier 1?

These antibodies target completely different proteins that share an acronym:

Aggrecan (AGC1) antibodies:

• Target a large extracellular matrix proteoglycan (~250 kDa core protein)

• Often used in cartilage, joint, and skeletal research

• Critical for studies on osteoarthritis, rheumatoid arthritis, and cartilage development

• Available as monoclonal antibodies like clone 4D7.1

Aspartate-glutamate carrier (AGC1) antibodies:

• Target a mitochondrial inner membrane transporter (~70-80 kDa)

• Used in metabolic research, particularly cancer metabolism

• Important for studies examining mitochondrial function and cellular redox status

• Critical in experiments examining glutamine dependency in cancer cells

Carefully check antibody datasheets to confirm which protein is being targeted.

How can I validate an AGC1 antibody before using it in critical experiments?

Proper validation is essential before using any AGC1 antibody:

• Positive controls: Use tissues/cells known to express AGC1 (cartilage for Aggrecan; proliferating cells for the aspartate-glutamate carrier)

• Negative controls: Use tissues/cells with low/no expression, or perform knockdown/knockout experiments to verify specificity

• Specificity testing: Compare to established antibodies and confirm expected molecular weight

• Cross-reactivity assessment: Test on samples from multiple species if working across species barriers

• Method-specific validation: Validate specifically for your application (Western blot, IHC, ELISA)

For Aggrecan research, consider testing antibody on both intact aggrecan and its degradation products, as proteolytic processing generates multiple fragments that may or may not contain your epitope.

For aspartate-glutamate carrier studies, AGC1 knockdown cells (as described in research articles) provide excellent negative controls to verify antibody specificity .

What ELISA protocols are recommended for AGC1 detection?

For sandwich ELISA detection of human Aggrecan (AGC1), follow this methodology:

Performance Specifications:

• Detection Range: 0.79-50 ng/mL

• Sensitivity: <0.39 ng/mL (MDD)

• Intra-Assay Precision: CV<10%

• Inter-Assay Precision: CV<15%

• Sample Recovery: 91-92% for cell culture media and serum

How should I quantify AGC1 ELISA results for maximum accuracy?

For accurate quantification of AGC1 by ELISA:

• Generate a standard curve using four-parameter logistic (4-PL) curve-fitting software, or alternatively, construct a standard curve by plotting mean absorbance against concentration on a log/log graph

• If data linearization is preferred, plot the log of AGC1 concentrations versus the log of optical density

• For diluted samples, multiply the concentration from the standard curve by the dilution factor

• Account for matrix effects by creating standards in the same matrix as your samples

• Assess linearity across multiple dilutions to confirm accurate quantification across the detection range

The documented linearity percentage ranges in different matrices are:

• Cell Culture Media: 81-109%

• Serum: 82-106%

What factors may affect AGC1 antibody performance in cell and tissue analysis?

Multiple factors can influence AGC1 antibody performance:

• Sample preparation issues:

  • Inadequate fixation may compromise epitope preservation

  • Overfixation can mask epitopes through protein cross-linking

  • For Aggrecan, enzymatic pretreatment with chondroitinase may be required to remove glycosaminoglycan chains that obscure protein core epitopes

• Expression variables:

  • For Aspartate-glutamate carrier AGC1, expression levels change under metabolic stress (e.g., higher protein expression following glutamine deprivation)

  • For Aggrecan, proteolytic processing produces multiple fragments with different molecular weights

• Experimental conditions:

  • Non-specific binding can occur in highly charged tissues like cartilage

  • Cell culture conditions affect AGC1 expression (glutamine availability influences aspartate-glutamate carrier levels)

  • Age-related changes in tissues alter Aggrecan structure and antibody reactivity

• Cross-reactivity concerns:

  • Some antibodies may cross-react with related proteoglycans

  • Validate specificity through appropriate controls

How can AGC1 antibodies be used to study cellular metabolism in cancer research?

AGC1 antibodies targeting the aspartate-glutamate carrier are valuable tools for cancer metabolism research:

• Expression analysis:

  • Measure AGC1 protein levels in different cancer types to correlate with metabolic phenotypes

  • Monitor AGC1 upregulation in response to glutamine deprivation

• Functional studies:

  • Use AGC1 antibodies in knockdown validation experiments

  • Employ AGC1 antibodies with immunoprecipitation to identify interaction partners

• Metabolic pathway investigation:

  • Combine with glutaminase inhibitor treatments (such as CB-839) to study compensatory metabolic mechanisms

  • Correlate AGC1 expression with aspartate levels and NAD+/NADH ratios

• Therapeutic target validation:

  • Monitor AGC1 expression in response to metabolic inhibitors

  • Assess AGC1 as a biomarker for tumors sensitive to glutaminase inhibition

Research demonstrates that AGC1 knockdown increases cancer cell vulnerability to glutamine limitation, suggesting potential therapeutic approaches targeting metabolic dependencies .

What are the considerations when studying AGC1 under various metabolic conditions?

When investigating AGC1 (particularly the aspartate-glutamate carrier) under different metabolic conditions:

• Glutamine availability:

  • AGC1 protein expression increases following glutamine deprivation

  • Cells with AGC1 knockdown show survival compromise in low-glutamine conditions (0.1mM vs. standard 4mM)

  • Cell death mechanisms involve apoptosis, detectable through Annexin V/PI staining and cleaved caspase 3

• Mitochondrial function:

  • Glutaminase inhibition (e.g., with CB-839) reduces mitochondrial oxygen consumption by approximately 50%

  • AGC1 deficiency doesn't alter respiratory response to glutaminase inhibition

• Metabolic flux:

  • AGC1 knockdown cells show altered carbon labeling patterns consistent with higher mitochondrial NAD+/NADH ratio

  • These cells release more 14C-CO2 from [U-14C]glutamine, indicating increased oxidative TCA cycling

• Sample collection timing:

  • AGC1 expression changes over time in response to metabolic stress

  • Standardize collection timepoints when comparing experimental conditions

• Functional rescue experiments:

  • Exogenous aspartate supplementation can rescue AGC1-KD cell viability in low-glutamine media

  • This provides important functional validation of antibody specificity

How can AGC1 antibodies be utilized in studying the malate-aspartate shuttle?

AGC1 antibodies are valuable for investigating the malate-aspartate shuttle (MAS), a critical system for transferring reducing equivalents from cytosol to mitochondria:

• Expression correlation studies:

  • Use AGC1 antibodies to quantify protein levels alongside other MAS components (GOT1, GOT2, MDH1, MDH2)

  • Proliferating cells display robust expression of MAS components

• Redox homeostasis investigation:

  • AGC1 knockdown reduces cellular NAD+/NADH ratio

  • This creates metabolic vulnerabilities that can be probed with simultaneous antibody detection of multiple metabolic enzymes

• Compartment-specific analysis:

  • Combine with cellular fractionation to distinguish mitochondrial from cytosolic effects

  • Use immunofluorescence with organelle markers to visualize AGC1 localization

• Metabolic compensatory mechanisms:

  • Monitor AGC1 expression changes when other shuttle components are inhibited

  • Investigate potential upregulation of AGC2 when AGC1 is knocked down

Research shows AGC1 knockdown affects cellular NAD+/NADH and pyruvate/lactate ratios, demonstrating its importance in cellular redox homeostasis .

What considerations are important when analyzing AGC1 antibody data in complex tissue samples?

When analyzing AGC1 antibody data from complex tissues:

• Cell type heterogeneity:

  • Different cell populations express varying levels of AGC1

  • Consider using cell-type specific markers in multiplexed analysis

  • Single-cell techniques may provide resolution of cell-specific expression

• Spatial distribution analysis:

  • For Aggrecan, distribution varies within cartilage zones

  • For the aspartate-glutamate carrier, mitochondrial distribution varies by cell type

  • Use high-resolution imaging to capture spatial heterogeneity

• Matrix effects:

  • Cartilage matrix can cause high background with some antibodies

  • Sample processing methods affect antigen retrieval efficiency

  • Validate ELISA performance in different matrices:

    • Serum recovery: 85-98%

    • Cell culture media recovery: 87-91%

• Normalization approaches:

  • Normalize to appropriate loading controls for Western blots

  • For tissue sections, normalize to cell number or tissue area

  • For ELISA data, construct standard curves in matrices matching your samples

• Cross-reactivity assessment:

  • Test for potential cross-reactivity with related proteins

  • For Aggrecan antibodies, validate specificity against other proteoglycans

How are AGC1 antibodies being used in cutting-edge cancer metabolism research?

AGC1 antibodies targeting the aspartate-glutamate carrier are enabling novel insights in cancer metabolism:

• Therapeutic vulnerability identification:

  • AGC1 loss reduces allograft tumor growth, which is further compromised by glutaminase inhibition (CB-839)

  • This suggests AGC1 inhibition could synergize with glutaminase inhibitors in cancer treatment

• Metabolic phenotyping:

  • AGC1 antibodies help characterize metabolic dependencies in different cancer types

  • Correlation between AGC1 expression and glutamine addiction phenotypes

• Aspartate metabolism research:

  • AGC1's role in exporting mitochondrial aspartate to cytosol is critical for nucleotide synthesis

  • Cancer cells with mitochondrial dysfunction may be particularly dependent on AGC1 function

• Combination therapy strategies:

  • Using AGC1 antibodies to measure protein changes during treatment with metabolic inhibitors

  • Identification of synthetic lethal interactions by combining AGC1 targeting with other metabolic interventions

• Biomarker development:

  • AGC1 expression levels may predict sensitivity to therapies targeting aspartate biosynthesis

  • Monitoring changes in AGC1 expression during disease progression or treatment response

Research demonstrates that mitochondrial aspartate export via AGC1 sustains cell survival in low-glutamine environments, suggesting potential therapeutic approaches for glutamine-dependent cancers .

What are the best practices for optimizing Western blot protocols for AGC1 detection?

For optimal Western blot detection of AGC1:

• Sample preparation:

  • For Aggrecan: Use specialized extraction buffers with protease inhibitors to prevent degradation

  • For Aspartate-glutamate carrier: Optimize mitochondrial isolation techniques

  • Consider sample fractionation to enrich for relevant cellular compartments

• Gel selection:

  • For Aggrecan: Use lower percentage gels (6-8%) due to its high molecular weight

  • For Aspartate-glutamate carrier: Standard 10-12% gels are typically suitable

• Transfer conditions:

  • For Aggrecan: Extended transfer times or specialized high-molecular-weight protocols

  • For Aspartate-glutamate carrier: Standard transfer conditions are usually adequate

• Blocking optimization:

  • Test both BSA and milk-based blocking buffers to determine optimal signal-to-noise

  • For phospho-specific detection, BSA is generally preferred over milk

• Antibody dilution optimization:

  • Perform dilution series to identify optimal concentration

  • Include proper positive and negative controls in each experiment

• Detection system selection:

  • For low abundance detection, consider enhanced chemiluminescence (ECL) or fluorescent systems

  • Quantitative analysis benefits from fluorescent secondary antibodies

How should researchers interpret conflicting AGC1 antibody results across different experimental systems?

When facing conflicting AGC1 antibody results:

• Epitope accessibility differences:

  • Post-translational modifications may mask epitopes in some experimental systems

  • For Aggrecan, proteolytic processing generates fragments that may contain or lack specific epitopes

  • For the aspartate-glutamate carrier, mitochondrial membrane integrity affects epitope accessibility

• Expression level considerations:

  • AGC1 expression varies with metabolic conditions and cell states

  • Glutamine deprivation increases AGC1 protein expression

  • Different cell lines show varying baseline expression levels

• Splice variant detection:

  • Antibodies may recognize different isoforms with varying efficiency

  • Confirm which isoforms your antibody detects and which are expressed in your model system

• Methodological differences resolution:

  • Direct comparison of antibody performance across methods (ELISA vs. Western blot vs. IHC)

  • Standardize sample preparation across experiments

  • Document inter-assay precision (CV<15% for ELISA)

• Validation approaches:

  • Use genetic approaches (siRNA, CRISPR) to create validated controls

  • Consider multiple antibodies targeting different epitopes

  • Rescue experiments (e.g., aspartate supplementation) provide functional validation

How can AGC1 antibodies contribute to understanding metabolic vulnerabilities in cancer?

AGC1 antibodies targeting the aspartate-glutamate carrier are revealing important metabolic vulnerabilities:

• Glutamine dependency mechanisms:

  • AGC1 knockdown cells show specific survival compromise in low-glutamine conditions

  • This death can be rescued by aspartate supplementation, indicating the critical role of aspartate delivery to the cytosol

• Synthetic lethality identification:

  • AGC1 loss synergizes with glutaminase inhibition to reduce cancer cell viability

  • This combination therapy approach reduces allograft tumor growth more than either intervention alone

• Metabolic flexibility assessment:

  • AGC1 antibodies help evaluate how cells adapt to metabolic stress

  • Different cancer cell lines show varying responses to glutamine deprivation and glutaminase inhibition

• Cell death mechanism investigation:

  • Glutamine starvation in AGC1-KD cells increases apoptotic markers (Annexin V/PI staining, cleaved caspase 3)

  • This allows detailed characterization of cell death pathways activated by metabolic stress

• Therapeutic target validation:

  • Research suggests AGC1 inhibition could be a promising approach for treating some cancers

  • AGC1 antibodies provide essential tools for monitoring treatment effects on protein expression

What are the latest methodological advances in AGC1 antibody application?

Recent methodological advances include:

• Recombinant antibody technology:

  • Preservative-free recombinant antibodies offer improved lot-to-lot consistency

  • Reduced background and increased specificity for challenging applications

• Multiplexed detection systems:

  • Simultaneous detection of AGC1 with other metabolic enzymes

  • Integration with mass spectrometry-based proteomics for comprehensive pathway analysis

• Live-cell imaging applications:

  • Membrane-permeable antibody fragments for tracking AGC1 dynamics

  • FRET-based approaches to monitor protein-protein interactions

• Proximity labeling techniques:

  • BioID or APEX2 fusions with AGC1 to identify proximal interacting proteins

  • Antibodies essential for validating identified interaction partners

• Single-cell analysis integration:

  • Antibody-based flow cytometry to quantify AGC1 levels in heterogeneous populations

  • Correlation with single-cell metabolomics for comprehensive phenotyping

• High-throughput screening applications:

  • Antibody-based assays to screen for compounds affecting AGC1 expression or function

  • ELISA-based approaches for rapid quantification across multiple samples

These advances continue to expand the utility of AGC1 antibodies in both basic research and translational applications.